Resverlogix's Lead Drug Featured in Key Scientific Publication
RVX-208 is the only Apo-Al/HDL drug to be highlighted
TSX Exchange Symbol: RVX
CALGARY, July 18 /PRNewswire-FirstCall/ -- Resverlogix Corp.
("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce
that Resverlogix's lead drug is featured prominently in an article
titled "Emerging Antidyslipidemic Drugs", which appears in the
current edition of Expert Opinion of Emerging Drugs, a well
respected scientific journal for the pharmaceutical industry. The
article written by Drs.' Pollex, Joy and Hegele provides an
overview of current and upcoming dyslipidemic drugs.
"To be the only ApoA-l/HDL drug highlighted in an esteemed
journal such as Expert Opinion of Emerging Drugs speaks volumes as
to the excitement felt in the scientific community for our lead
drug RVX-208," stated Donald McCaffrey, President and CEO of
Resverlogix. "The data provided to the authors was our preclinical
data. The Phase 1a data which we recently announced illustrated
very similar trending as the African Green Monkey data of increased
ApoA-I production and HDL functionality, thus our enthusiasm
continues to build as we head into our Phase 1b/2a trial later this
year."
RVX-208 is a first-in-class small molecule that facilitates
endogenous ApoA-I production. It is positioned as one of the most
promising emerging drugs in the treatment of atherosclerosis, the
largest medical market in the world with a critical unmet need. To
the Company's knowledge RVX-208 is the only novel small molecule
that is specifically designed to increase ApoA-I production.
Consequently this raises functional HDL levels which in turn
enhance reverse cholesterol transport, atherosclerosis regression
and ultimately reduction of major adverse cardiovascular events
(MACE).
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) program is the
Company's primary focus which is to develop novel small molecules
that enhance ApoA-I. These vital therapies address the grievous
burden of atherosclerosis and other important diseases such as
acute coronary syndrome, diabetes, Alzheimer's disease and other
vascular disorders. The Company's secondary focus is TGF-Beta
Shield(TM), a program that aims to address burgeoning grievous
diseases, such as cancer and fibrosis. Resverlogix Corp. trades on
the Toronto Stock Exchange (TSX:RVX). For further information
please visit www.resverlogix.com.
This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.
Source: Resverlogix Corp.
CONTACT: Theresa Kennedy, VP, Corporate Communications,
Resverlogix
Corp., Phone: (604) 538-7072, Email: Theresa@resverlogix.com; Ken
Lebioda, SVP
Business & Corporate Dev't, Resverlogix Corp., Phone: (403)
254-9252, Email:
Ken@resverlogix.com; Website:
www.resverlogix.com
 |
Posted: July 2008
